Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Combination of reverse and chemical genetic screens reveals angiogenesis inhibitors and targets.

Kalén M, Wallgard E, Asker N, Nasevicius A, Athley E, Billgren E, Larson JD, Wadman SA, Norseng E, Clark KJ, He L, Karlsson-Lindahl L, Häger AK, Weber H, Augustin H, Samuelsson T, Kemmet CK, Utesch CM, Essner JJ, Hackett PB, Hellström M.

Chem Biol. 2009 Apr 24;16(4):432-41. doi: 10.1016/j.chembiol.2009.02.010.

2.

Identification of novel angiogenesis inhibitors.

Sridhar J, Akula N, Sivanesan D, Narasimhan M, Rathinavelu A, Pattabiraman N.

Bioorg Med Chem Lett. 2005 Sep 15;15(18):4125-9.

PMID:
15993586
3.

A zebrafish in vivo phenotypic assay to identify 3-aminothiophene-2-carboxylic acid-based angiogenesis inhibitors.

Papakyriakou A, Kefalos P, Sarantis P, Tsiamantas C, Xanthopoulos KP, Vourloumis D, Beis D.

Assay Drug Dev Technol. 2014 Nov-Dec;12(9-10):527-35. doi: 10.1089/adt.2014.606.

4.

A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells.

Ma YL, Lin SW, Fang HC, Chou KJ, Bee YS, Chu TH, Chang MC, Weng WT, Wu CY, Cho CL, Tai MH.

Int J Mol Sci. 2014 Sep 19;15(9):16611-27. doi: 10.3390/ijms150916611.

5.
6.

Endothelial cell spheroids as a versatile tool to study angiogenesis in vitro.

Heiss M, Hellström M, Kalén M, May T, Weber H, Hecker M, Augustin HG, Korff T.

FASEB J. 2015 Jul;29(7):3076-84. doi: 10.1096/fj.14-267633. Epub 2015 Apr 9.

7.

Tick troponin I-like molecule is a potent inhibitor for angiogenesis.

Fukumoto S, Sakaguchi T, You M, Xuan X, Fujisaki K.

Microvasc Res. 2006 May;71(3):218-21. Epub 2006 Apr 24.

PMID:
16631826
8.

Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish.

Tran TC, Sneed B, Haider J, Blavo D, White A, Aiyejorun T, Baranowski TC, Rubinstein AL, Doan TN, Dingledine R, Sandberg EM.

Cancer Res. 2007 Dec 1;67(23):11386-92.

9.

Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin.

Shibuya T, Watanabe K, Yamashita H, Shimizu K, Miyashita H, Abe M, Moriya T, Ohta H, Sonoda H, Shimosegawa T, Tabayashi K, Sato Y.

Arterioscler Thromb Vasc Biol. 2006 May;26(5):1051-7. Epub 2006 Mar 9.

11.

Induced thyme product prevents VEGF-induced migration in human umbilical vein endothelial cells.

Krill D, Madden J, Huncik K, Moeller PD.

Biochem Biophys Res Commun. 2010 Dec 17;403(3-4):275-81. doi: 10.1016/j.bbrc.2010.11.014. Epub 2010 Nov 10.

PMID:
21073864
12.

Anti-angiogenic effects and mechanisms of zerumin A from Alpinia caerulea.

He ZH, Gilli C, Yue GG, Lau CB, Greger H, Brecker L, Ge W, But PP.

Food Chem. 2012 May 1;132(1):201-8. doi: 10.1016/j.foodchem.2011.10.057. Epub 2011 Oct 25.

PMID:
26434281
13.

Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis.

Hussain S, Slevin M, Matou S, Ahmed N, Choudhary MI, Ranjit R, West D, Gaffney J.

Angiogenesis. 2008;11(3):245-56. doi: 10.1007/s10456-008-9108-2. Epub 2008 Mar 11.

PMID:
18330714
14.

Development of a one-step embryonic stem cell-based assay for the screening of sprouting angiogenesis.

Hermant B, Desroches-Castan A, Dubessay ML, Prandini MH, Huber P, Vittet D.

BMC Biotechnol. 2007 Apr 16;7:20.

15.

Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish.

Camus S, Quevedo C, Menéndez S, Paramonov I, Stouten PF, Janssen RA, Rueb S, He S, Snaar-Jagalska BE, Laricchia-Robbio L, Izpisua Belmonte JC.

Oncogene. 2012 Sep 27;31(39):4333-42. doi: 10.1038/onc.2011.594. Epub 2011 Dec 19.

PMID:
22179836
16.

Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.

Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, Liu ET, Kohn EC, Libutti SK.

Biotechniques. 2002 Sep;33(3):664-6, 668, 670.

PMID:
12238776
17.

Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay.

Cross LM, Cook MA, Lin S, Chen JN, Rubinstein AL.

Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):911-2. No abstract available.

18.

A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation.

Radi M, Evensen L, Dreassi E, Zamperini C, Caporicci M, Falchi F, Musumeci F, Schenone S, Lorens JB, Botta M.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5579-83. doi: 10.1016/j.bmcl.2012.07.014. Epub 2012 Jul 13.

PMID:
22853993
19.

YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, Liu L, Zhu Y, Zeng J, Lei Q, Pan Y, Wei Y, Zhao Y, Yu L.

Sci Rep. 2014 Aug 12;4:6031. doi: 10.1038/srep06031.

20.

SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.

Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, Shi S, Cheng L, Pan Y, Feng S, Zhao X, Deng H, Yang S, Wei Y.

Clin Cancer Res. 2011 Jul 1;17(13):4439-50. doi: 10.1158/1078-0432.CCR-10-3109. Epub 2011 May 27.

Supplemental Content

Support Center